Article
Any T-cell-mediated disease benefits from therapy without affecting other inflammatory pathways
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Health Canada approves Biocon's Yesafili, biosimilar to Eylea
3 Things You Should Know About Interventional Glaucoma Comanagement
Nicox completes phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertension
Patient-Centered Treatment Strategies in the Management of nAMD and DME
Nanoscope Therapeutics forms Vision Advisory Committee
Sanaregen Vision Therapeutics invites prospective investors to reserve stock shares